Synergy Health Network’s $100 Mil Expansion Starts with Crowdfunding via Rialto Markets

Ambitious ‘telehealth’ care company Synergy Health Network wants to be generating revenues of $100 million in just four years.

The Florida-based firm, founded by tech-savvy entrepreneur Brian Weinstein in November 2021, already generates $4.2 million annually by connecting patients to a broad range of healthcare services manned by specialists, rather than relying on AI (artificial intelligence) as preferred by many of its competitors.

Now it is giving investors the chance to back its expansion plans after teaming up with Rialto Markets to utilise the award-winning broker-dealer’s crowdfunding platform and infrastructure for a $1 million Reg CF raise to launch Synergy’s four-year growth mission.

“We are delighted Synergy Healthcare Network has chosen to work with us and use our platform and infrastructure to attract the investment to launch its four-year expansion project and hopefully deliver a healthy return on investment.”

“A US Department of Health report shows a 63-fold increase in the utilization of telehealth services from 840,000 in 2019 to 52.7 million in 2021 and is increasing. The US telehealth market is expected to expand at a compound annual growth rate of 31.2% from 2022 to 2027.

“We hope investors will seize the opportunity we are offering through Rialto Markets’ platform.”

Crowdfunding is now a popular way for innovative private companies to raise investment. The phenomenon raised $113.52 billion globally last year, according to Pitchbook data, a year-on-year increase of 1,021%.

Rialto Markets also operates a pioneering secondary market alternative trading system (ATS) which empowers the buying and selling of shares in private companies.

The ATS operates in a similar way as the Nasdaq and NYSE are used for public company trading, allowing private companies to access vital funding and investors to have more flexibility with liquifying holdings.

This includes equity crowdfunded companies and other forms of private securities including NFTs, crypto currencies and other types of digital assets in a much more regulated environment.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”